Maciejewski B, Skladowski K, Pilecki B, Taylor J M, Withers R H, Miszczyk L, Zajusz A, Suwinski R
Centre of Oncology, M. Skłodowska-Curie Memorial Institute, Gliwice, Poland.
Radiother Oncol. 1996 Aug;40(2):137-45. doi: 10.1016/0167-8140(96)01776-8.
Toxicity of an accelerated 7 days per week fractionation schedule (arm A) was evaluated and compared with a conventional 5 days per week treatment (arm B) in a randomized trial.
Forty-four patients with squamous cell carcinoma of the head and neck in stage T2-4Nzero-1Mzero were included in the study. Total dose and dose per fraction of 2.0 Gy given once-a-day at 24 h intervals were the same in both arms of the trial. The only difference was the overall treatment time being 5 weeks in arm A and 7 weeks in arm B.
Analysis of severe mucosal reactions shows significant difference between arm A and B, with regard to both maximum score and duration of severe mucositis. Confluent mucositis (score > 15 according to the Dische system) lasting longer than 3 weeks developed in 48% of patients in arm A and only in 5% in arm B. In group A seven (30%) late effects (osteo- and soft tissue necrosis) occurred during 7-12 month follow-up with two reactions (10%) in group B being suspected as late effects. There was significant association between acute reactions and late effects in arm A, suggesting that the late effects are consequential.
The high incidence of severe acute reactions and consequential late effects suggests that the accelerated treatment in arm A (using daily fractions of 2.0 Gy, 7 days per week) gives unacceptable toxicity.
在一项随机试验中,评估每周7天加速分割方案(A组)的毒性,并与传统的每周5天治疗方案(B组)进行比较。
44例T2-4N0-1M0期头颈部鳞状细胞癌患者纳入本研究。试验的两组中,每天一次、间隔24小时给予的总剂量和每次分割剂量均为2.0 Gy。唯一的区别是A组的总治疗时间为5周,B组为7周。
严重黏膜反应分析显示,A组和B组在严重黏膜炎的最高评分和持续时间方面存在显著差异。A组48%的患者出现融合性黏膜炎(根据迪斯切系统评分>15),持续时间超过3周,而B组仅5%的患者出现。在A组,7-12个月的随访期间发生了7例(30%)晚期效应(骨和软组织坏死),B组有2例反应(10%)被怀疑为晚期效应。A组的急性反应和晚期效应之间存在显著关联,表明晚期效应是由急性反应导致的。
严重急性反应和继发性晚期效应的高发生率表明,A组的加速治疗方案(每周7天,每天分割剂量2.0 Gy)产生了不可接受的毒性。